Market reactionShares rose 14% on Nov 3.
Alterity Therapeutics is developing ATH434, an oral drug for multiple system atrophy (MSA), a fatal rare brain disease; it is not approved.
Alterity's oral ATH434 has a functional benefit signal in MSA, but ATH434-201 missed its brain-iron primary endpoint. FDA agreed that one pivotal Phase 3 plus confirmatory evidence could support approval; Alterity expects ATH434-201 to provide that evidence. Phase 3 operational activities have begun. Cash was A$41.3 million at 30 September 2026, including the tax refund and option proceeds, while discussions to support Phase 3 funding continue. The investment case depends on financing the pivotal program and confirming the functional benefit.
Thesis checklist
1 risk needs attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: Phase 3 starts by year-end 2026
Does Alterity initiate the pivotal trial with funding to complete it?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
ATH434 Phase 3 preparations advance; funding remains the next hurdle
FDA-aligned Phase 3 design in hand for an MSA drug with no approved rivals, but starting Phase 3 depends on a partnership or financing
FDA-aligned Phase 3 path for ATH434 in fatal rare MSA disease, contingent on pivotal trial delivering the efficacy Phase 2 signaled
ATH434's Phase 2 MSA efficacy signal sets up a Phase 3 bet on whether iron chelation can deliver registrational proof of disease modification
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Neurology and pain
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
2 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.